CYTO Archives - Page 2 of 3

Developments

Altamira’s Bentrio nasal spray approved in Malaysia

Altamira Therapeutics’ (NASDAQ:CYTO) Bentrio nasal spray has been approved by the Medical Device Authority of Malaysia for the protection against airborne allergens and viruses and is cleared for commercialization in...

January 21, 2022

Executive Moves

Altamira updates RNA therapeutics program with new CDO, NIH grant

Altamira Therapeutics (NASDAQ:CYTO), in a business update on its development activities in RNA therapeutics, appointed Covadonga Pañeda, Ph.D., as chief development officer for RNA therapeutics, effective in early April...

January 13, 2022

Developments

Altamira updates Bentrio EU roll-out, 510(k), new Asian distribution, COVID-19, allergy testing

Altamira Therapeutics (NASDAQ:CYTO) issued a business update on Bentrio, its nasal spray for protection against airborne viruses and allergens. The company has set up contracts with wholesalers in its lead market of...

December 30, 2021

Developments

Altamira randomizes first patients in Bentrio trial in house dust mite allergy

Altamira Therapeutics (NASDAQ:CYTO) randomized the first group of patients in a clinical trial with Bentrio (AM-301) in house dust mite allergic rhinitis. Bentrio, a drug-free nasal spray intended for personal...

December 16, 2021

Developments

Altamira randomizes first patient in Bentrio trial in seasonal allergic rhinitis

Altamira Therapeutics (NASDAQ:CYTO) randomized the first patient in its NASAR trial for the clinical evaluation of Bentrio (AM-301) in seasonal allergic rhinitis (SAR). Bentrio, a drug-free nasal spray intended for...

December 1, 2021

Developments

Posters on use of Altamira’s RNA delivery platforms presented at AHA scientific sessions

Altamira Therapeutics (NASDAQ:CYTO) announced the presentation of data at the American Heart Association scientific sessions from two studies by a research group at Washington University, St. Louis, on the use of the...

November 15, 2021

Developments

Altamira posts positive Bentrio nasal spray data in Sars-CoV-2 Delta variant

Altamira Therapeutics (NASDAQ:CYTO) reported positive efficacy data from testing its Bentrio nasal spray in vitro against the Delta variant of the SARS-CoV-2 virus. Bentrio is a drug-free nasal spray for...

November 12, 2021

Developments

Altamira, Wellesta in LOU to distribute Bentrio in 6 key Asian markets

Altamira Therapeutics (NASDAQ:CYTO) signed a letter of understanding (LOU) with Singapore’s Wellesta Holdings for the marketing and distribution of Bentrio, its nasal spray for protection against airborne viruses and...

October 25, 2021

Developments

FDA accepts Altamira 510(k) application for Bentrio

Altamira Therapeutics’ (NASDAQ:CYTO) 510(k) application for premarket clearance for its Bentrio nasal spray for protection against airborne allergens was accepted for review by the FDA. The application now moves to a...

October 14, 2021

Developments

Altamira Therapeutics files Bentrio 510(k) for allergy indication

Altamira Therapeutics’ (NASDAQ:CYTO) Bentrio is an OTC nasal spray that is drug- and preservative-free and designed to provide triple protection against airborne viruses and allergens. First, it helps to protect the...

September 27, 2021

Tag - CYTO

Altamira’s Bentrio nasal spray approved in Malaysia

Altamira updates RNA therapeutics program with new CDO, NIH grant

Altamira updates Bentrio EU roll-out, 510(k), new Asian distribution, COVID-19, allergy testing

Altamira randomizes first patients in Bentrio trial in house dust mite allergy

Altamira randomizes first patient in Bentrio trial in seasonal allergic rhinitis

Posters on use of Altamira’s RNA delivery platforms presented at AHA scientific sessions

Altamira posts positive Bentrio nasal spray data in Sars-CoV-2 Delta variant

Altamira, Wellesta in LOU to distribute Bentrio in 6 key Asian markets

FDA accepts Altamira 510(k) application for Bentrio

Altamira Therapeutics files Bentrio 510(k) for allergy indication

General

More